Annovis Bio Inc
ANVS
Company Profile
Business description
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Contact
101 Lindenwood Drive
Suite 225
MalvernPA19355
USAT: +1 484 875-3192
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,126.90 | 73.70 | 0.92% |
| CAC 40 | 7,876.36 | 85.65 | 1.10% |
| DAX 40 | 22,539.98 | 376.49 | 1.70% |
| Dow JONES (US) | 41,760.44 | 241.32 | -0.57% |
| FTSE 100 | 8,634.80 | 51.99 | 0.61% |
| HKSE | 23,206.84 | 87.26 | 0.38% |
| NASDAQ | 17,290.56 | 8.73 | -0.05% |
| Nikkei 225 | 35,624.48 | 6.92 | 0.02% |
| NZX 50 Index | 12,312.60 | 42.60 | 0.35% |
| S&P 500 | 5,592.52 | 19.33 | -0.34% |
| S&P/ASX 200 | 7,925.20 | 81.80 | 1.04% |
| SSE Composite Index | 3,348.44 | 12.69 | 0.38% |